多家医院儿科急诊量明显上升，低龄儿童抗病毒流感用药有望迎来新选择

Core Insights - The treatment options for influenza antiviral therapy in children under 5 years old are currently limited in China, with only neuraminidase inhibitors like Oseltamivir approved for this age group [1][2] - There is a significant increase in pediatric emergency visits due to influenza, with hospitals reporting a rise of approximately 20% in emergency cases [1] - The H3N2 strain of influenza poses a greater risk this year compared to last year's H1N1, leading to increased concerns about severe complications in children [1] Group 1: Current Treatment Landscape - The only approved antiviral treatment for children under 5 is Oseltamivir, which has some adverse effects such as nausea and vomiting, and requires a 5-day regimen [2] - There is a rising trend in resistance rates according to national influenza monitoring data, indicating a substantial unmet need for effective antiviral treatments for young children [2] Group 2: Research and Development - A clinical study led by a team from Beijing Children's Hospital is evaluating the safety and efficacy of Marbofloxacin suspension in children aged 1 to under 5, which could expand treatment options for this demographic [2] - Marbofloxacin is the first innovative antiviral RNA polymerase inhibitor approved in China in the last 20 years, but it is currently only approved for those aged 5 and older [2] - The market for pediatric influenza antiviral drugs is expanding, with domestic companies like Senju Pharmaceutical and Qifeng Kairui developing new treatments aimed at younger patients [3]